Staff WriterBen Turner is a writer and journalist based in London. He graduated in 2015 with a Master’s degree in Physics. He is particularly interested in the translation of early scientific discoveries into cutting-edge tech.
The Copenhagen biotech's acquisition of Encycle Therapeutics demonstrates growing market interest in peptide-based drugs.
Zealand Pharma, a Copenhagen-based biotech company focused on the development of...
Tandem and Dexcom system aces closed-loop pancreas trial for type 1 diabetes, but doesn't appear to break new ground over existing market competitor.
A clinical...
Pharma giant Bayer is pursuing ambitious collaborations with Longevity-based companies, but Roundup pressure continues to mount.
Bayer AG, the multinational pharmaceutical and life sciences company,...
University of Oslo researchers develop AI biomarker for tracking neurological treatment over time.
Finding timely therapies for age begins with finding a way to measure...
New Age-tech fund will capitalise upon trend towards “multi-generational living"
4Gen Ventures, a new venture capital fund entering the Agetech space, plans to begin investing...
As the longevity investor's new fund turns 8 months old this month, we went five for five with Sergey Young.
Longevity.Technology: We often find people...
Max Planck researchers find changes across mere months, that are possibly reversed by brain training by telomore shortening.
The tips of our chromosomes, known as...
